[Pubmed] Lipoprotein Receptor-Related Protein 4 Antibody Positivity in the Youngest Patient in the Caucasus Region: A Ca

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6515
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Android Chrome

[Pubmed] Lipoprotein Receptor-Related Protein 4 Antibody Positivity in the Youngest Patient in the Caucasus Region: A Ca

Message par RSS-Bot »


Cureus. 2024 Sep 8;16(9):e68961. doi: 10.7759/cureus.68961. eCollection 2024 Sep.

ABSTRACT

Juvenile myasthenia gravis is a rare disorder where antibodies targeting the acetylcholine receptor or, less frequently, muscle-specific kinase can be detected in the serum while about half of the patients can be seronegative. A pediatric patient with ocular myasthenia is presented whose serum was negative for acetylcholine receptor and muscle-specific kinase antibodies but tested positive for low-density lipoprotein receptor-related protein 4 antibodies. A favourable clinical response was observed to medical treatment with pyridostigmine and prednisolone, as expected in isolated ocular juvenile myasthenia gravis. This case exemplifies the very rare association of juvenile myasthenia gravis with low-density lipoprotein receptor-related protein 4 positivity, reported in only a few cases so far. The specificity of the antibody and the efficiency of medical treatment emphasize the importance of clinical suspicion and appropriate serological testing in juvenile myasthenia gravis in the absence of acetylcholine receptor and muscle-specific kinase antibodies.

PMID:39385918 | PMC:PMC11463899 | DOI:10.7759/cureus.68961


Source: https://pubmed.ncbi.nlm.nih.gov/3938591 ... t9+e462414
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »